The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst)
An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors.
 
Takashi Kojima
Honoraria - Oncolys BioPharma
Patents, Royalties, Other Intellectual Property - Astellas Amgen BioPharama (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Toshiyoshi Fujiwara
Consulting or Advisory Role - Oncolys BioPharma
 
Yasuhiro Shirakawa
No Relationships to Disclose
 
Hiromi Ono
No Relationships to Disclose
 
Masako Nakamoto
No Relationships to Disclose
 
Hiromi Hasegawa
No Relationships to Disclose
 
Nami Hirano
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Chugai Pharma
 
Shogo Nomura
Employment - Asahi Kasei (I)
 
Yosuke Togashi
No Relationships to Disclose
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Zenyaku Kogyo (Inst)
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Sumitomo Dainippon; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)